Boehringer Ingelheim’s New Launch Senvelgo® Revolutionizes Feline Diabetes Treatment
Over 300 veterinarians and feline medicine enthusiasts gathered on February 2 for the presentation of Boehringer Ingelheim’s latest innovation, Senvelgo®. This new oral antidiabetic is set to revolutionize the management of feline diabetes.
The presentation, titled “Senvelgo®, the revolution in the treatment of feline diabetes,” was conducted by Diego Esteban, a veterinarian at the Barcelona Feline Clinic and accredited in Feline Medicine by AVEPA. Esteban highlighted the groundbreaking features of Senvelgo® during the XII GEMFE congress (Group of Specialists in Feline Medicine).
Senvelgo® is the first liquid oral treatment for feline diabetes, offering once-daily administration and effectively reducing blood glucose levels in diabetic cats. It simplifies the monitoring of diabetic cat treatment, allowing both cats and their owners to maintain a normal life despite the disease.
Unlike existing treatments, Senvelgo® is presented in an oral solution format, with the dose adjusted to the cat’s weight (1mg/kg/day). It has shown high effectiveness in reducing hyperglycemia in just one week, without presenting a risk of clinical hypoglycemia. Senvelgo® also eliminates the need for glucose curves for patient monitoring.
Feline diabetes is on the rise, largely due to the lifestyle habits of felines, such as obesity and a sedentary lifestyle. Although the current incidence of feline diabetes in Spain is relatively low (approximately 3 out of every 100 cats), it significantly impacts the quality of life of both the animals and their caregivers. Senvelgo® is expected to reduce premature abandonment of treatment as it greatly facilitates monitoring with its simple and practical administration.
Boehringer Ingelheim’s introduction of Senvelgo® further solidifies the company’s expertise in diabetes treatment, following the success of ProZinc in dogs.
The presentation of Senvelgo® took place during the 12th edition of the GEMFE congress, themed “Reproduction, traumatology, and behavior.” The congress, held from February 2-4 in A Coruña, saw Boehringer Ingelheim participate as a sponsor and feature a Senvelgo® stand in the commercial exhibition area.
The Group of Feline Medicine Specialists (GEMFE), affiliated with AVEPA, aims to improve medical care and promote the well-being of cats through education, research, and knowledge sharing.